JP2008512491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512491A5 JP2008512491A5 JP2007531416A JP2007531416A JP2008512491A5 JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5 JP 2007531416 A JP2007531416 A JP 2007531416A JP 2007531416 A JP2007531416 A JP 2007531416A JP 2008512491 A5 JP2008512491 A5 JP 2008512491A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor cell
- cell population
- cells
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/937,658 US20060057127A1 (en) | 2004-09-10 | 2004-09-10 | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| PCT/US2005/032357 WO2006031703A1 (en) | 2004-09-10 | 2005-09-09 | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512491A JP2008512491A (ja) | 2008-04-24 |
| JP2008512491A5 true JP2008512491A5 (enExample) | 2008-10-02 |
Family
ID=36034247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531416A Withdrawn JP2008512491A (ja) | 2004-09-10 | 2005-09-09 | 前立腺癌の処置のためのサイトカイン発現細胞ワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060057127A1 (enExample) |
| EP (1) | EP1789082A4 (enExample) |
| JP (1) | JP2008512491A (enExample) |
| CN (1) | CN101076351A (enExample) |
| CA (1) | CA2577989A1 (enExample) |
| WO (1) | WO2006031703A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7901902B2 (en) | 2006-07-27 | 2011-03-08 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying a cellular immune response against prostate cancer |
| US8378084B2 (en) * | 2006-12-22 | 2013-02-19 | The Regents Of The University Of California | Fusion molecule based on novel TAA variant |
| ATE555212T1 (de) * | 2007-03-02 | 2012-05-15 | Biosante Pharmaceuticals Inc | Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs |
| US8840881B2 (en) * | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| JP6042802B2 (ja) | 2010-04-27 | 2016-12-14 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 新生物（腫瘍）を治療するための免疫原性組成物及び方法。 |
| EA201492284A1 (ru) | 2012-06-27 | 2015-11-30 | Берг Ллк | Применение маркеров в диагностике и лечении рака предстательной железы |
| US10512595B2 (en) | 2014-01-14 | 2019-12-24 | The Procter & Gamble Company | Multi-step product for improving the appearance and feel of human skin |
| US9931285B2 (en) | 2014-01-14 | 2018-04-03 | The Procter & Gamble Company | Multi-step product for improving the appearance and feel of human skin |
| US20150196464A1 (en) | 2014-01-14 | 2015-07-16 | The Procter & Gamble Company | Cosmetic Composition |
| US10206859B2 (en) | 2014-07-29 | 2019-02-19 | The Procter & Gamble Company | Cosmetic composition |
| EP4242329A3 (en) | 2014-12-08 | 2023-10-25 | Berg LLC | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US6544771B1 (en) * | 1987-12-11 | 2003-04-08 | Cell Genesys, Inc. | Retroviral gene therapy vectors and therapeutic methods based thereon |
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US6133028A (en) * | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| ATE336587T1 (de) * | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6093570A (en) * | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6040183A (en) * | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| US6548286B1 (en) * | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| AU741602B2 (en) * | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| WO2000026676A1 (en) * | 1998-11-03 | 2000-05-11 | Cell Genesys, Inc. | Cancer-associated antigens and methods of their identification |
-
2004
- 2004-09-10 US US10/937,658 patent/US20060057127A1/en not_active Abandoned
-
2005
- 2005-09-09 JP JP2007531416A patent/JP2008512491A/ja not_active Withdrawn
- 2005-09-09 CN CNA2005800385268A patent/CN101076351A/zh active Pending
- 2005-09-09 CA CA002577989A patent/CA2577989A1/en not_active Abandoned
- 2005-09-09 WO PCT/US2005/032357 patent/WO2006031703A1/en not_active Ceased
- 2005-09-09 EP EP05796370A patent/EP1789082A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Oxygen‐deficient molybdenum oxide nanosensitizers for ultrasound‐enhanced cancer metalloimmunotherapy | |
| JP2008512491A5 (enExample) | ||
| DE602005015990D1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| ATE494303T1 (de) | An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs | |
| WO2010037514A3 (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| JP2010516259A5 (enExample) | ||
| JP2011525191A5 (enExample) | ||
| DE602005008731D1 (de) | Durch röntgen- und/oder uv-strahlen aktivierbare partikel, deren herstellung und deren therapeutische oder diagnostische verwendung | |
| ATE276758T1 (de) | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid | |
| CA2354046A1 (en) | New cancer treatments | |
| ATE389712T1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
| JP2012021028A5 (enExample) | ||
| ATE525908T1 (de) | Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen | |
| IL180612A0 (en) | Materials and methods for immune system stimulation | |
| WO2003061591A3 (en) | Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| EP2385060A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| WO2010045573A3 (en) | Tumor vaccine | |
| AU2599002A (en) | Fusion cells and cytokine compositions for treatment of disease | |
| AR041086A1 (es) | Vacuna | |
| SI1530628T1 (sl) | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine | |
| WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| ATE521629T1 (de) | Matrixmetalloproteinase-11-impfstoff |